Morrisville public company looks to divest subsidiary after CEO tried to buy it


NightHawk Biosciences is planning to divest one of its subsidiaries amid financial challenges.

Previous TD Private Client Wealth fined $600,000 and censured by FINRA
Next Aro Biotherapeutics raises $41.5M from investors in its second multimillion-dollar financing of 2023